Glycemic Control with Improvement in HOMA2 IR and HOMA2 Beta: Impact of Digital Twin Enabled Precision Nutrition for Remission of Diabetes

Paramesh Shamanna [1], Shashank Joshi [2], L.isa Shah [3], Mala Dharmalingam [4], Arun Vadavi [5], Suresh Damodaran [6], Jahangir Mohammed [3], Maluk Mohamed [1], Terrence Poon [3], Ashok Keshavamurthy [1], Thajudeen Mohamed [1], Suchitra Bhonsley [1]

1) Twin Health, Bangalore, India, India (2) Joshi Clinic, Lilavati and Bhatia Hospital, Endocrinology, Mumbai, India (3) Twin Health, Mountain View, United States of America (4) RAMAIAH MEDICAL COLLEGE AND HOSPITALS, Endocrinology, Bangalore, India (5) Sudha Prevention Center, Diabetes, Bangalore, India (6) Sri Ramakrishna Hospital, Endocrinology, Coimbatore, India

Abstract

Background and aims: Technology enabled precision nutrition, a combination of macro, micro and biota nutrients, along with Continuous Glucose Monitoring (CGM) have been demonstrated to be a key for reversal of diabetes. We sought to investigate the possible association between change in the glycated hemoglobin (HbA1c), insulin sensitivity (HOMA 2 Beta) and insulin resistance (HOMA 2 IR). These parameters were evaluated as the longitudinal follow up for three months

Materials and methods: We conducted an initial analysis (n=63) of the ongoing randomized controlled trial of Twin Precision Treatment (TPT): a novel whole-body digital twin enabled precision treatment for reversing diabetes. The TPN program entailed detailed patient food intake information with CGM readings as inputs to a machine learning. The machine learning algorithm integrated these multi-dimensional data to predict personalized postprandial glucose response. This leads to a predictive model, which enabled daily precision nutrition guidance to the patient. Physicians utilized, TWIN app recommendations based on the CGM values as a decision tool to down titrate medications

Results: The mean age (years) was 41 (±9.2, minimum 16, maximum 62, 95% CI 39 to 44). The duration of diabetes (years) was 3.1 (±2.7, maximum 8, 95% CI 2.4 to 3.8). There was a statistically significant improvement in HbA1c % (8.5 ± 1.6, 95% CI 8.17 to 8.99 reduced to 5.6 ± 0.52, 95% CI 5.52 to 5.79; p<0.0001), HOMA2-IR (1.81 ± 0.71, 95% CI 1.63 to 1.99 decreased to 1.11 ± 0.51, 95% CI 0.98 to 1.24; p<0.0001), HOMA2 Beta (51.78 ± 28, 95% CI 44.6 to 58.97 increased to 94.42 ± 38.9, 95% CI 84.62 to 104.2; p<0.0001). 54% (n=34) and 37% (n=23) patients achieved complete (HbA1c<5.7) and partial remission (HbA1c<6.5), respectively. At 90 days, HbA1c in the range of 6.5-7% was achieved by five patients and one patient had HbA1c of 7.1%. 43% (n=27) patients at enrolment had normal HOMA2 Beta (>54.2), which changed to 88% (n=56). 22% (n=14) patients at enrolment had normal HOMA2 IR (<1.22), which changed to 70% (n=44). There was a significant negative correlation for the change in the HOMA2 beta and HbA1c (Pearson r - 0.38, 95% CI -0.57 to -0.14, p= 0.0021). There was a negative correlation for the change in the HOMA2IR and HbA1c (Pearson r - 0.18, 95% CI -0.411 to 0.068, p= 0.15 ns). At 90 days, all patients were off medications, other than two patients on metformin monotherapy. The mean Time Above Range (TAR) at baseline was 39.9%, reduced to 1.7 % and Time In Range (TIR) at baseline was 58%, increased to 74.8%)

Conclusion: The HbA1c and HOMA2IR decreased by 34% and 39%, respectively with 82% increase in HOMA2Beta, from baseline. 90% (n=57) achieved complete/ partial remission. Technology enabled precision nutrition, a combination of macro, micro and biota nutrients, with physician-led adoption and technology-driven intervention had positive implications for diabetes remission with improvement in insulin sensitivity and beta cell function.

Keywords: Digital, Remission

Funding and Conflicts of Interest
None